Genovate Biotechnology Co., Ltd.

As of March 31, 2026, Genovate Biotechnology Co., Ltd. carries a market capitalization of 4.44B, placing it among publicly traded companies globally. Its enterprise value stands at 3.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Genovate Biotechnology Co., Ltd. has 136.75M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 8.71, and the price-to-book ratio stands at 2.23.

As of March 31, 2026, Genovate Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 160.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.34B versus a market cap of 4.44B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Genovate Biotechnology Co., Ltd. maintains a current ratio of 12.67, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.08, indicating conservative leverage, while an interest coverage ratio of 33.59 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Genovate Biotechnology Co., Ltd. posted a negative return on equity (ROE) of -0.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.50, reflecting losses generated across the asset base. The company generates approximately 2.49M in revenue per employee across its workforce of 189.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.28 indicates how many times Genovate Biotechnology Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Genovate Biotechnology Co., Ltd. recorded an income tax benefit of -987,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.15M and -9.17M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 21, 2026, Genovate Biotechnology Co., Ltd.'s stock has gained approximately 48.39% over the past 52 weeks. The 50-day moving average sits at 26.65, while the 200-day moving average is 27.06.

Over the twelve months ended March 31, 2026, Genovate Biotechnology Co., Ltd. generated 471.48M in revenue and converted that into -9.17M in net income, yielding earnings per share of -0.07. EBITDA reached 20.79M, while operating income came in at -17.22M.

As of March 31, 2026, Genovate Biotechnology Co., Ltd. holds 1.11B in cash and equivalents against 1.57M in total debt, resulting in a net debt position of -352.36M. Total book value stands at 1.99B, with working capital of 1.24B providing operational flexibility.

Genovate Biotechnology Co., Ltd. produced 1.81M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -42.11M in capital expenditures, free cash flow totaled -40.30M - equivalent to -0.32 per share.

Over the twelve months ended March 31, 2026, Genovate Biotechnology Co., Ltd. posted a gross margin of 34.58, reflecting its pricing power and cost economics. The operating margin of -3.65 and net profit margin of -1.94 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Genovate Biotechnology Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.13, meaning Genovate Biotechnology Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Genovate Biotechnology Co., Ltd.'s most recent stock split took place on January 14, 2026 with a 892:921 split ratio.

As of March 31, 2026, Genovate Biotechnology Co., Ltd. has an Altman Z-Score of 25.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.